The Publisher regrets that this article is an accidental duplication of an article that has already been published, 10.1016/j.repc.2022.03.007. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.repc.2023.01.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding the scale and nature of avoidable healthcare-associated harm for prisoners in England: protocol for a retrospective cross-sectional study.
BMJ Open
December 2024
Centre for Mental Health and Safety, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
Introduction: Around 1 in 20 patients experience avoidable healthcare-associated harm worldwide. Despite longstanding concerns, there is insufficient information available about the safety of healthcare for prisoners. To address this, this study will investigate the scale and nature of avoidable healthcare-associated harm for prisoners in England.
View Article and Find Full Text PDFSmoking cessation and harm reduction: a systematic overview of ongoing, randomized controlled trials.
BMC Psychiatry
December 2024
Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, Pauwelsstraße 30, Aachen, 52074, Germany.
Background: Smoking remains one of the major public health threats, necessitating substantial scientific and societal interest in further developing and implementing systematic, smoking cessation trials. This review examines ongoing randomized controlled trials (RCTs) on smoking cessation and harm reduction, focusing on adherence to German S3 guidelines for tobacco dependence and identifying areas needing further research and neglected aspects in the implementation of treatment guidelines for tobacco dependence.
Methods: A systematic search was conducted on the International Clinical Trials Registry Platform, comprising multiple trial registries worldwide, to identify ongoing RCTs focusing on smoking cessation and harm reduction.
Antihypertensive Treatment Patterns in CKD Stages 3 and 4: The CKD-REIN Cohort Study.
Kidney Med
December 2024
Centre for Research in Epidemiology and Population Health, Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.
Article Synopsis
- Blood pressure (BP) control is crucial for preventing complications in chronic kidney disease (CKD), yet many patients struggle to reach target levels; this study evaluates how antihypertensive prescriptions change over time in CKD patients.
- Conducted with 2,755 hypertensive CKD patients in France, the study tracked factors influencing prescription changes, such as patient demographics and healthcare provider interactions.
- Results showed that over five years, there was a high rate of changes in medication; poor adherence to medications increased the likelihood of needing additional drugs, while having a lower education level led to more frequent withdrawals of antihypertensive medications.
Why and when could nucleos(t)ide analogues treatment be withdrawn?
Dig Liver Dis
October 2024
Liver Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses of Pisa University Hospital; Department of Clinical and Experimental Medicine, University of Pisa, Italy; Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy. Electronic address:
Article Synopsis
- - Oral antiviral therapy with nucleos(t)ide analogues (NUCs) effectively reduces hepatitis B virus (HBV) levels, but achieving a functional cure (clearance of HBsAg) is uncommon.
- - While stopping NUC treatment can lead to HBsAg loss in 10% to 20% of patients, there's a high risk of virological relapse (50% to 80%) and the need for retreatment (40% to 55%).
- - Research is ongoing into using viral and immune biomarkers for better patient management post-treatment, along with AI-driven strategies for tailored NUC therapy decisions.
[Professional Pharmaceutical Care Services. A case report].
Farm Comunitarios
October 2024
Profesora Titular, Departamento de Medicina Física y Farmacología, Facultad Farmacia, Universidad La Laguna, Santa Cruz de Tenerife. España.
Case Presentation: A 73-year-old woman, independent, with a medical history of psychopathology under treatment and non-compliant. After a fall, he suffered a forearm fracture and, in this context, abuse of psychoactive drugs and non-steroidal antiinflammatory drugs was suspected.
Study And Evaluation Of The Case: The state of the patient's situation was evaluated, and an abuse of the hypnotic-anxiolytic treatment was observed, which could be related to her recent forearm fracture.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!